RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Edouard Louis  ¹     Remo Panaccione  ²     Gareth Parkes  ³     Marc Ferrante  ⁴     Ken Takeuchi  ⁵     Britta Siegmund  ⁶     Phillip Levine  ⁷     Jasmina Kalabic  ⁸     Ezequiel Neimark  ⁸     Kori Wallace  ⁹     Su Chen  ⁹     Rachel Duan  ⁹     Alessandro Armuzzi  ¹⁰     Luc Biedermann  ¹¹     Gil Y. Melmed  ¹²     Stefan Schreiber  ^13    
1 University Hospital CHU of Liège, Liège, Belgium
² University of Calgary, Calgary, Canada
³ Barts Health NHS Trust, London, United Kingdom
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
⁶ Berlin Institute of Health, Berlin, Germany
⁷ AbbVie, Inc., North Chicago, United States
⁸ AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
⁹ AbbVie, Inc, North Chicago, United States
¹⁰ IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
¹¹ USZ Zürich, Zürich, Switzerland
¹² Cedars Sinai Medical Center, Los Angeles, United States
¹³ University Hospital Schleswig-Holstein, Kiel, Germany

Topic
Endoscopy, IBD

Session
IL-23-Blockers in IBD: Part 1

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)